Medical research

Painkiller undermines aspirin's anti-clotting action

Millions of Americans take Celebrex for arthritis or other pain. Many, if they are middle-aged or older, also take a low-dose aspirin tablet daily to reduce the risk of heart attack and stroke. Yet they may be getting little ...

Medical research

Ticagrelor: Considerable added benefit for specific patients

Since the start of 2011, the active ingredient ticagrelor can be prescribed in Germany in addition to acetylsalicylic acid (ASA) to avoid blood clots in patients with acute ischaemia of the cardiac muscle. The German Institute ...

Cardiology

Protein inhibitor holds promise for heart disease treatment

UC Davis scientists have developed a novel cardiovascular agent which, unlike currently available drugs for heart disease, does not target high blood cholesterol or high blood pressure. The experimental agent inhibits C-reactive ...

Cardiology

No increase in bleeding complications with rivaroxaban post-ACS

Patients with acute coronary syndrome who were treated with the blood-thinning drug rivaroxaban in addition to an antiplatelet medication (clopidogrel or ticagrelor) experienced no increase in bleeding complications compared ...

Cardiology

Evacetrapib fails to reduce major adverse cardiovascular events

Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol ...

Cardiology

Lixisenatide doesn't affect cardiovascular risk in T2DM

(HealthDay)—The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent acute coronary syndrome, according ...

page 2 from 18